Recruiting
Phase 3

CBD-OS

Sponsor:

Jazz Pharmaceuticals

Code:

NCT07723976

Conditions

Developmental and Epileptic Encephalopathy (DEE)

Eligibility Criteria

Sex: All

Age: 1+

Healthy Volunteers: Not accepted

Interventions

CBD-OS

Placebo

Study Details

Brief summary:

The efficacy, safety, and tolerability of CBD-OS have been evaluated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous sclerosis complex (TSC). The current JZP926-303 study is being conducted to evaluate the safety and efficacy of CBD-OS in participants with Developmental and Epileptic Encephalopathy (DEE).

Conditions

Developmental and Epileptic Encephalopathy (DEE)

Study ID

NCT07723976

Start date

Oct 30, 2026

Status verified date

Nov, 2026

Completion date

Sep 4, 2029

Anticipated

Primary completion date

Sep 4, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 1+

Healthy Volunteers: Not accepted

Participants are eligible to be included in the study only if all the following criteria apply:

1. Is at least 1 year of age at the time of signing the informed consent/assent.
2. Meets the clinical phenotype for DEE as specified in the protocol.
3. Per the investigator, the underlying etiology contributes to developmental impairment and seizures.
4. Has had, or is willing to complete, confirmatory imaging and/or genetic testing to determine etiology of DEE.
5. Is currently receiving antiseizure intervention, such as treatment with a stable regimen of at least 1 ASM or an established intervention for epilepsy (eg, ketogenic diet or neurostimulation).
6. All medications or interventions for epilepsy have been stable for ≥ 28 days prior to starting the baseline period (Visit 2) with no planned changes to the regimen for the duration of the Double-blind Treatment Period.

Participants are excluded from the study if any of the following criteria apply:

1. Has a concurrent, confirmed diagnosis of non-epileptic seizures or events that can confound the assessment of the efficacy measures, in the opinion of the investigator.
2. The etiology of the participant's seizures is a progressive neurologic disease.
3. Has known or suspected hypersensitivity to cannabinoids or any of the excipients of the study intervention, such as sesame oil.
4. Has an active central nervous system (CNS) infection, demyelinating disease, degenerative neurologic disease, or any CNS disease deemed to be progressive during the study that may confound the interpretation of the study results (including autoimmune encephalitis).
5. Is currently being treated with Epidiolex or recently received treatment with Epidiolex within 28 days prior to screening.
6. Has experienced a lack of efficacy and/or poor tolerability to an adequate treatment regimen of Epidiolex based on medical history and the clinical judgement of the investigator. Participants who discontinued treatment for reasons other than safety, tolerability, or lack of efficacy and previously received Epidiolex ≥ 28 days prior to starting the Baseline Period (Visit 2) may be eligible for the study after consultation with the medical monitor and/or sponsor representative.
7. Has been taking felbamate for less than 12 months prior to screening. Participants who are stable on felbamate for ≥ 12 months are eligible for inclusion.

Study Design

Enrollment

120 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: CBD-OS

Participants with DEE will be randomized to CBD-OS up to 10 mg/kg twice daily for a 6-week treatment period.

placebo comparator: Placebo

Participants with DEE will be randomized to matching placebo for a 6-week treatment period.

experimental: Open-Label Extension: CBD-OS

Participants with DEE who completed the double-blind phase of the study and enter the optional OLE will begin a 22-week open-label treatment period with CBD-OS up to 10 mg/kg twice daily following a 2-week Blinded Transition Period.

Interventions

CBD-OS

Oral solution, twice daily

Placebo

Oral solution, twice daily

Primary outcome measure

  • Change in Countable Motor Seizure Frequency Per 28 Days [ Time Frame: Baseline up to 6 weeks of double-blind treatment period ]

Central Contacts and Locations

Central contacts

Clinical Trial Disclosure & Transparency

215-832-3750ClinicalTrialDisclosure@JazzPharma.com

Locations

Hawaii Pacific Neuroscience (HPN) Comprehensive Epilepsy Center

Recruiting

Honolulu, Hawaii, United States, 96817

Mid Atlantic Epilepsy And Sleep Center (ESC)

Recruiting

Bethesda, Maryland, United States, 20817

More Information

Sponsor

Jazz Pharmaceuticals

Last update posted

Nov 17, 2026

Last verified

Nov, 2026

Keywords

  • Developmental and Epileptic Encephalopathy
  • JZP926-OS
  • CBD-OS

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by Jazz Pharmaceuticals on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.